The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Open accessAbstract
CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only two studies had an overall low risk of bias 33,79 ; five had unclear risk [72][73][74][75][76] , and nine had high risk 30,31,36,37,39,41,77,78,81 .”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
In the citing paper
“Earlier studies that dominated the conclusions of some previous meta-analyses (e.g., the omega-3 trial 33 ) were likely false positives.”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Cited by
Sorted by citations
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Polyunsaturated fatty acids and their metabolites in brain function and disease
Bazinet, R. P., & Layé, S. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3820 · Cited by 1,703
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Self-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Rebooting psychotherapy research and practice to reduce the burden of mental illness
Kazdin, A. E., & Blase, S. L. (2011) · Perspectives on Psychological Science · doi:10.1177/1745691610393527 · Cited by 1,254
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationKahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Self-citationSchneider, M., Debbané, M., Bassett, A. S., Chow, E. W. C., Fung, W. L. A., van den Bree, M. B. M., Owen, M., Murphy, K. C., Niarchou, M., Kates, W. R., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070864 · Cited by 779
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
WALSH, R. N. (2011) · American Psychologist · doi:10.1037/a0021769 · Cited by 763
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 584
An Individualized Risk Calculator for Research in Prodromal Psychosis
Cannon, T. D., Yu, C., Addington, J., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., Heinssen, R., Jeffries, C. D., Mathalon, D. H., McGlashan, T. H., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15070890 · Cited by 574
DHA Effects in Brain Development and Function
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsløf, L. B. S., Ciappolino, V., & Agostoni, C. V. (2016) · Nutrients · doi:10.3390/nu8010006 · Cited by 566
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Self-citationMeta-analysis of oxidative stress in schizophrenia.
Flatow, J., Buckley, P., & Miller, B. J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.018 · Cited by 491
Early interventions to prevent psychosis: systematic review and meta-analysis
Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P., & Kendall, T. (2013) · BMJ · doi:10.1136/bmj.f185 · Cited by 456
Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A. P., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M. B., Foley, D. L., Brewer, W. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1270 · Cited by 434
Self-citationEPA guidance on the early detection of clinical high risk states of psychoses
Schultze‐Lutter, F., Michel, C., Schmidt, S. J., SCHIMMELMANN, B. G., Marić, N. P., Salokangas, R. K. R., Riecher‐Rössler, A., van der Gaag, M., Nordentoft, M., Raballo, A., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.010 · Cited by 405
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
van der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D. H., Yung, A. R., McGorry, P., & Cuijpers, P. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.004 · Cited by 384
Self-citationTreasure, J., Stein, D., & Maguire, S. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12170 · Cited by 353
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. L. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 377
Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review
Trépanier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.90 · Cited by 360
Morrison, A. P., French, P., Stewart, S. L. K., Birchwood, M., Fowler, D., Gumley, A. I., Jones, P. B., Bentall, R. P., Lewis, S. W., Murray, G. K., et al. (2012) · BMJ · doi:10.1136/bmj.e2233 · Cited by 332
Neuroplastic changes in depression: A role for the immune system
Eyre, H., & Baune, B. T. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.03.019 · Cited by 319
Inflammation and Schizophrenia
Kirkpatrick, B. W., & Miller, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt141 · Cited by 326
Neuroinflammation in schizophrenia especially focused on the role of microglia
Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314
Docosahexaenoic Acid (DHA): An Ancient Nutrient for the Modern Human Brain
Bradbury, J. (2011) · Nutrients · doi:10.3390/nu3050529 · Cited by 328
Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases
Sun, G. Y., Simonyi, Á., Fritsche, K. L., Chuang, D. Y., Hannink, M., Gu, Z., Greenlief, C. M., Yao, J. K., Lee, J. C., & Beversdorf, D. Q. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.03.006 · Cited by 324
Biomarkers and clinical staging in psychiatry
McGorry, P. D., Keshavan, M. S., Goldstone, S. D., Amminger, G. P., Allott, K., Berk, M., Lavoie, S., Pantelis, C., Yung, A. R., Wood, S. J., et al. (2014) · World Psychiatry · doi:10.1002/wps.20144 · Cited by 324
Self-citationAntioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A. C., & Tsai, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 286
Inflammation and the two-hit hypothesis of schizophrenia
Feigenson, K. A., Kusnecov, A., & Silverstein, S. M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 293
McGorry, P. D., Nelson, B., Goldstone, S. D., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 301
Self-citationA critique of the “ultra‐high risk” and “transition” paradigm
van Os, J., & Guloksuz, S. (2017) · World Psychiatry · doi:10.1002/wps.20423 · Cited by 261
McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2902 · Cited by 262
Self-citationEvolving the future: Toward a science of intentional change
Wilson, D. S., Hayes, S. C., Biglan, A., & Embry, D. D. (2014) · Behavioral and Brain Sciences · doi:10.1017/s0140525x13001593 · Cited by 255
Smaga, I., Niedzielska, E., Gawlik, M., Moniczewski, A., Krzek, J., Przegaliński, E., Pera, J., & Filip, M. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.015 · Cited by 252
Nutritional Psychiatry: Where to Next?
Jacka, F. N. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.020 · Cited by 273
Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis
Davies, C., Cipriani, A., Ioannidis, J. P. A., Radua, J., Stahl, D., Provenzani, U., McGuire, P., & Fusar‐Poli, P. (2018) · World Psychiatry · doi:10.1002/wps.20526 · Cited by 229
Liu, J. J., Green, P., Mann, J. J., Rapoport, S. I., & Sublette, M. E. (2014) · Brain Research · doi:10.1016/j.brainres.2014.11.059 · Cited by 242
Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Ermakov, E. A., Dmitrieva, E. M., Parshukova, D. A., Kazantseva, D. V., Vasilieva, A. R., & Smirnova, L. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8881770 · Cited by 256
Developmental Vitamin D Deficiency and Risk of Schizophrenia: A 10-Year Update
McGrath, J. J., Burne, T. H. J., Feron, F. P., Mackay‐Sim, A., & Eyles, D. W. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq101 · Cited by 231
Addington, J., Epstein, I., Liu, L., French, P., Boydell, K. M., & Zipursky, R. B. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.015 · Cited by 226
Cultures for mental health care of young people: an Australian blueprint for reform
McGorry, P. D., Goldstone, S. D., Parker, A. G., Rickwood, D. J., & Hickie, I. B. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00082-0 · Cited by 221
Self-citationPreventing progression to first-episode psychosis in early initial prodromal states
Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., Brockhaus-Dumke, A., Berning, J., Janssen, B., Decker, P., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066357 · Cited by 224
Self-citationAntioxidants as potential therapeutics for neuropsychiatric disorders
Pandya, C. D., Howell, K. R., & Pillai, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.017 · Cited by 222
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Nutrition and mental health: A review of current knowledge about the impact of diet on mental health
Grajek, M. K., Krupa-Kotara, K. H., Białek-Dratwa, A., Sobczyk, K., Grot, M., Kowalski, O., & Staśkiewicz‐Bartecka, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.943998 · Cited by 265
Rutter, M. (2011) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2011.02367.x · Cited by 218
Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases
Nakagawa, Y., & Chiba, K. (2014) · Pharmaceuticals · doi:10.3390/ph7121028 · Cited by 215
Fusar‐Poli, P., Bechdolf, A., Taylor, M. J., Bonoldi, I., Carpenter, W. T., Yung, A. R., & McGuire, P. K. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs060 · Cited by 211
van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M. C., Koeter, M., Cuijpers, P., Wunderink, L., & Linszen, D. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs105 · Cited by 209
Hickie, I. B., Scott, E. M., Cross, S. P., Iorfino, F., Davenport, T. A., Guastella, A. J., Naismith, S. L., Carpenter, J. S., Rohleder, C., Crouse, J. J., et al. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50383 · Cited by 208
Su, K.-P., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Chang, J. P.-C., Chang, H.-C., & Pariante, C. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.008 · Cited by 205
Larson, M. K., Walker, E. F., & Compton, M. T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.93 · Cited by 203
Fineberg, A. M., & Ellman, L. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.001 · Cited by 206
Miklowitz, D. J., O’Brien, M. P., Schlosser, D. A., Addington, J., Candan, K. A., Marshall, C., Domingues, I., Walsh, B. C., Zinberg, J. L., De Silva, S. D., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.04.020 · Cited by 200
Correll, C. U., Hauser, M., Auther, A. M., & Cornblatt, B. A. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02235.x · Cited by 204
The treatment of cognitive impairment in schizophrenia
GOFF, D. C., Hill, M. B., & Barch, D. M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 203
Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study
Amminger, G. P., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., & McGorry, P. D. (2015) · Nature Communications · doi:10.1038/ncomms8934 · Cited by 188
Self-citationPrediction and Prevention of Psychosis in Youth at Clinical High Risk
Addington, J., & Heinssen, R. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143146 · Cited by 189
Encapsulation of fish oil in soybean protein particles by emulsification and spray drying
Giorgio, L. D., Salgado, P. R., & Mauri, A. N. (2018) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2018.09.024 · Cited by 187
Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis
Hutton, P., & Taylor, P. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000354 · Cited by 184
Emotion Recognition in Individuals at Clinical High-Risk for Schizophrenia
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Schlögelhofer, M., Mossaheb, N., Werneck‐Rohrer, S., Nelson, B., & McGorry, P. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr015 · Cited by 192
Self-citationAttenuated psychosis syndrome in DSM-5
Tsuang, M. T., van Os, J., Tandon, R., Barch, D. M., Bustillo, J., Gäebel, W., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.004 · Cited by 210
Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data
Bozzatello, P., Brignolo, E., Grandi, E. D., & Bellino, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080067 · Cited by 193
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
The Alberta Pregnancy Outcomes and Nutrition (APrON) cohort study: rationale and methods
Kaplan, B. J., Giesbrecht, G. F., Leung, B. M. Y., Field, C. J., Dewey, D., Bell, R. C., Manca, D. P., O’Beirne, M., Johnston, D. W., Pop, V. J. M., et al. (2012) · Maternal and Child Nutrition · doi:10.1111/j.1740-8709.2012.00433.x · Cited by 174
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Barron, H., Hafizi, S., Andreazza, A. C., & Mizrahi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030651 · Cited by 183
Omega-3 fatty acids and mental health
Lange, K. W. (2020) · Global Health Journal · doi:10.1016/j.glohj.2020.01.004 · Cited by 191
Catalán, A., de Pablo, G. S., Vaquerizo‐Serrano, J., Mosillo, P., Baldwin, H., Fernández‐Rivas, A., Moreno, C., Arango, C., Correll, C. U., Bonoldi, I., et al. (2020) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13322 · Cited by 176
Preti, A., & Cella, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.026 · Cited by 167
Orešič, M., Seppänen‐Laakso, T., Sun, D., Tang, J. P., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. M., et al. (2012) · eScholarship (California Digital Library) · Cited by 168
Logan, A. C., & Jacka, F. N. (2014) · Journal of PHYSIOLOGICAL ANTHROPOLOGY · doi:10.1186/1880-6805-33-22 · Cited by 181
A systematic review of metabolite biomarkers of schizophrenia
Davison, J., O’Gorman, A., Brennan, L., & Cotter, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.09.021 · Cited by 161
Sánchez‐Villegas, A., Galbete, C., Martínez‐González, M. Á., Martínez, J. A., Razquín, C., Salas‐Salvadó, J., Estruch, R., Buil‐Cosiales, P., & Martí, A. (2011) · Nutritional Neuroscience · doi:10.1179/1476830511y.0000000011 · Cited by 171
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Lieberman, J. A., Small, S. A., & Girgis, R. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19080865 · Cited by 165
Implications for reactive oxygen species in schizophrenia pathogenesis
Koga, M., Serritella, A. V., Sawa, A., & Sedlak, T. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.022 · Cited by 164
Do, K. Q., Cuenod, M., & Hensch, T. K. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv065 · Cited by 158
Amminger, G. P., Schäfer, M. R., Klier, C. M., Slavik, J.-M., Holzer, I., Holub, M., Goldstone, S. D., Whitford, T., McGorry, P. D., & Berk, M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.167 · Cited by 158
Self-citationAttachment, Neurobiology, and Mentalizing along the Psychosis Continuum
Debbané, M., Salaminios, G., Luyten, P., Badoud, D., Armando, M., Solida-Tozzi, A., Fonagy, P., & Brent, B. K. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00406 · Cited by 177
A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder
Bent, S., Bertoglio, K., Ashwood, P., Bostrom, A., & Hendren, R. L. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1078-8 · Cited by 156
Koutsouleris, N., Borgwardt, S., Meisenzahl, E. M., Ronald Bottlender, A., Möller, H., & Riecher‐Rössler, A. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr145 · Cited by 156
Ultra high-risk state for psychosis and non-transition: A systematic review
Simon, A. E., Velthorst, E., Nieman, D. H., LINSZEN, D. H., Umbricht, D., & de Haan, L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.002 · Cited by 155
Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148
Davis, J., Moylan, S., Harvey, B. H., Maes, M. H. J., & Berk, M. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533012 · Cited by 145
Emotion recognition impairment is present early and is stable throughout the course of schizophrenia
Comparelli, A., Corigliano, V., Carolis, A. D., Mancinelli, I., Trovini, G., Ottavi, G., Dehning, J., Tatarelli, R., Brugnoli, R., & Girardi, P. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.11.005 · Cited by 146
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Mei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., et al. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102005 · Cited by 143
Self-citationRandomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis
McGorry, P. D., Nelson, B., Phillips, L., Yuen, H. P., Francey, S. M., Thampi, A., Berger, G. E., Amminger, G. P., Simmons, M. B., Kelly, D., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07785 · Cited by 144
Self-citationMossaheb, N., Becker, J., Schaefer, M. R., Klier, C. M., Schloegelhofer, M., Papageorgiou, K., & Amminger, G. P. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.008 · Cited by 142
Self-citationOmega 3 polyunsaturated fatty acids and the treatment of depression
Deacon, G., Kettle, C., Hayes, D., Dennis, C., & Tucci, J. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2013.876959 · Cited by 149
Benbrook, C. M., Butler, G., Latif, M. A., Leifert, C., & Davis, D. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082429 · Cited by 155
Metadata
- Authors
- Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
- Affiliations
- Medical University of Vienna (AT)
- The University of Melbourne (AU)
- Clienia AG (CH)
- ORCID
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-02-01
- Volume
- 67
- Issue
- 2
- Pages
- 146
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2130372506
- Cited by
- 896
- References
- 45
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
- FWCI
- 92.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute (03T-315)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
